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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the benefits and harms of modifying dietary fat intake in the treatment of gallstone disease.
B A C K G R O U N D
Gallstone disease, also known as cholelithiasis, is characterised as
hard deposits or stones in the gallbladder and biliary tract. A nor-
mally functioning gallbladder stores bile and releases it into the
small intestine when it is needed for digestion. Gallstones can
develop if the bile contains too much cholesterol or bilirubin, if
the gallbladder is dysfunctional, or if the release of bile is im-
paired. The type of gallstone is defined by its composition and
can be divided into two main groups, those that are cholesterol-
rich, which comprise approximately 70% of patients from West-
ern countries, and those that are composed predominantly of bile
pigments (Venneman 2010).
Recognised risk factors for the disease include female sex, hered-
itary predisposition, increasing age and body mass index (BMI),
rapid weight loss, diabetes, and gastrointestinal and biliary fac-
tors, including infection. Prevalence of cholesterol gallstones is
generally considered to be increasing as a consequence of nutri-
tional and lifestyle changes, ageing populations, the increasing
global prevalence of obesity, and improved diagnostic capabilities
(Stinton 2010; Stokes 2014a; Aune 2016).
Gallstones canbe diagnosed on the basis ofmedical history, clinical
findings, and imaging, the most appropriate method of which is
abdominal ultrasound imaging,which is supported by high quality
evidence (EASL 2016).
Surgery for gallstones is associated with a mortality of less than
2% of all surgical deaths (Scollay 2011). The burden of morbidity,
and direct and indirect costs are high. For example, in the USA,
the estimated cost of treating gallstone disease is approximately
USD 6.2 billion annually (Stinton 2010; Stokes 2014a).
Description of the condition
People who develop cholelithiasis may have no symptoms at all,
while others may experience severe abdominal pain (biliary colic),
nausea, and vomiting. It is estimated that approximately 10% of
the population with asymptomatic gallstones will develop symp-
toms or require treatment within five years (Halldestam 2004).
These include cholecystitis, and less commonly, obstructive jaun-
dice, cholangitis, acute pancreatitis, and gangrene of the gallblad-
der.
1Modified dietary fat intake for treatment of gallstone disease (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Description of the intervention
Symptomatic gallstone disease is often treated by surgically re-
moving the gallbladder (cholecystectomy), most commonly un-
dertaken laparoscopically (EASL 2016; Keus 2006). While this
may be common practice, medical management can also be a first
line treatment and can include dissolving the gallstones with drug
therapy (for example, with ursodeoxycholic acid (May 1993)).
However, traditionally, restricting dietary fat intake was used to
reduce the pain associated with gallbladder contractions, rather
than dissolving the gallstones. A survey of dietary practice in the
UK published 20 years ago indicated that people were regularly
advised to restrict fat to manage their gallstone disease, but at that
time, there was limited empirical evidence to justify this approach
(Madden 1992). Mogadam 1984 also reported that dietary fat
restriction was a frequent method of management, but contested
the therapeutic relevance of this form of dietary management.
Currently, authoritative sources of information for people with
gallstone disease advise adherence to low fat, low cholesterol diets,
or both (British Liver Trust 2011; Radio 4 2012; Patient 2014;
BUPA 2015). This suggests that a dietary intervention is still cur-
rent treatment for this disease, even though the rationale appears
to be uncertain. A preliminary review of the literature indicates
that there is no published evidence of the benefits of a low fat diet
compared with standard diet. However, with the increasing preva-
lence of obesity, there is evidence that people with obesity, who
are advised to follow weight-reducing diets that incorporate a very
low fat diet, may be more likely to develop gallstones (Festi 2000),
and that diets higher in fat may reduce gallstone risk in adults
losing weight (Stokes 2014b). We do not anticipate that specific
populations would experience different outcomes from interven-
tions.
How the intervention might work
The rationale for restricting or modifying dietary fat in the treat-
ment of gallstone disease has two putative mechanisms.
First, as dietary fat is a potent stimulator of gallbladder contrac-
tion, dietary fat may provoke or exacerbate post-prandial pain,
and therefore, hypothetically, restricting dietary fat might re-
duce pain. However, the gallbladder also contracts spontaneously
(Behar 1989), and in response to an intake of mixed meals, pro-
tein (Hopman 1985), or cephalic stimulation (Hopman 1987).
Furthermore, if restricting dietary fat does lead to a reduction in
gallbladder contractions and emptying, it may also increase the
risk of gallstone deposition, as lithogenic bile would be retained
longer in the gallbladder. thus potentially exacerbating the prob-
lems.
Second, reducing total dietary fat, and particularly saturated fat,
leads to a reduction in plasma cholesterol. Lower plasma choles-
terol levels may be accompanied by a parallel reduction in bil-
iary cholesterol concentration, which would reduce the precipi-
tation of cholesterol in the bile, and decrease the risk of forming
cholesterol-rich gallstones (Mendez-Sanchez 2007). This poten-
tial mechanism is complicated by the fact that circulating choles-
terol levels are more influenced by endogenous cholesterol synthe-
sis than by the intake of dietary cholesterol per se (Lecerf 2011).
If this mechanism provides a rationale for the potential treatment
of cholesterol-rich stones, it is unlikely to be relevant to the man-
agement of stones composed predominantly of pigment.
Why it is important to do this review
Evidence for the role of dietary intervention in the primary pre-
vention of gallbladder stones in adults is currently under review
(Stokes 2014a). Dietary advice to restrict or modify fat intake,
which is currently promoted as treatment for people with gall-
stones, does not appear to be based on rationalised evidence.While
there are general health benefits associated with avoiding excessive
dietary fat, i.e. reduced risk of obesity and cardiovascular disease,
specific benefits for the treatment of gallstone disease need clari-
fication (NICE 2014). First, it is important to determine if there
are benefits frommodifying fat intake, or detrimental effects from
reduced gallbladder emptying. Second, it would be informative
to quantify the amount of fat reduction needed, so that tailored
advice could be given, in particular to the minority of patients
with gallstone disease who are underweight and potentially at risk
of malnutrition.
This review will systematically examine the evidence for the di-
etary management of gallstone disease, clarify the therapeutic ben-
efits and potential risks of dietary interventions as alternatives to,
or interim measures while waiting for surgical intervention, and
identify the need for future research.
O B J E C T I V E S
To assess the benefits and harms of modifying dietary fat intake in
the treatment of gallstone disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised clinical trials for assessments of ben-
efits and harms.
Wewill only include non-randomised studies or quasi-randomised
studies for assessment of harms. We will not search specifically for
such studies, and are aware that this is a limitation of our review.
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Types of participants
We will include trials in which the participants have gallstone dis-
ease, were diagnosed using ultrasound, and are receiving a dietary
intervention, which may or may not have the primary purpose of
treating gallstones.
Participants can be male or female, of any age, or ethnic origin.
We will exclude trials with participants who have been diagnosed
with another condition that may compromise dietary fat toler-
ance, e.g. cholestatic liver disease, short bowel, intestinal failure,
or pancreatic insufficiency.
Types of interventions
We will include trials in which the intervention examines the ben-
eficial or harmful effects, or both, of any type of modification of
dietary fat intake compared with standard care (no specific addi-
tional or alternative intervention), or compared with any other
type of dietarymodification, providing that fat intake can be quan-
tified in both study groups, i.e. as either grams of fat per day or
per test meal, or expressed as percentage energy. We will conduct
these analyses separately. The intervention might include, for ex-
ample, restriction of total fat intake, modification of cholesterol
intake, long chain fatty acid intake, saturated fat intake, plants
sterols and stanols, and fat from specific sources, such as dairy fat
or animal fat. We will also include trials in which the intervention
examines the beneficial or harmful effects of dietary components
that have an effect on fat absorption or reabsorption of bile acids,
e.g. psyllium or soluble fibre (Ganji 1994; Theuwissen 2008). In
some cases, we may identify trials that compare modified dietary
fat against another format of modified dietary fat, or against an-
other dietary intervention that may not have a modified dietary
fat component, for example, modified dietary fat versus vitamin
C intake, or adjustments to fibre intake.
We will include trials with any level of dietary fat modification,
providing that it differs from the comparison group.
Some trials may have different modes of delivery to the gastroin-
testinal tract, e.g. oral or enteral nutrition, both of which we will
include. However, we will exclude trials where the intervention
or comparison are exclusively parenteral, i.e. include no oral or
enteral intake.
We will include trials that test the effects of the frequency and
timing of dietary fat intake.
We will also include trials that have three or more dietary inter-
ventions, as long as one of the groups contains a form of dietary
modification as described above, and we will take account of ad-
ditional groups during analysis, as described below.
We will include trials that include a co-intervention, e.g. drugs, if
the trial groups have received the same proportion of drug inter-
vention with a dietary modification, or if there are separate groups
in the trial in which there have been no drug co-interventions.
Types of outcome measures
Primary outcomes
• All-cause mortality and gallstone morbidity, i.e.
documented cholecystitis, gallstone pancreatitis, biliary colic,
obstructive jaundice, and cholangitis.
• Dissolution or reduction in size of gallstones.
• Serious adverse events. Depending on the availability of
data, we will attempt to classify adverse events as serious or non-
serious. We will define a serious adverse event according to the
International Conference on Harmonisation (ICH) Guidelines for
Good Clinical Practice, as any untoward medical occurrence that
results in death, is life-threatening, requires inpatient
hospitalisation or prolongation of existing hospitalisation, results
in persistent or significant disability or incapacity, or is a
congenital anomaly or birth defect, or any medical event that
might jeopardise the patient, or requires an intervention to
prevent it (ICH-GCP 1997). All other adverse events (that is,
any medical occurrence, not necessarily having a causal
relationship with the treatment, but leading to a dose reduction
or discontinuation of the treatment) are considered non-serious.
• Health-related quality of life, assessed using validated tests.
Secondary outcomes
• Number of patients admitted to hospital.
• Number of patients subjected to a surgical intervention.
• Number of people with non-serious adverse events.
Search methods for identification of studies
Electronic searches
We will identify studies by searching the Cochrane Hepato-
Biliary Group Controlled Trials Register (Gluud 2017), the
Cochrane Central Register of Controlled Trials (CENTRAL) in
the Cochrane Library, MEDLINE Ovid, Embase Ovid, and Sci-
ence Citation Index Expanded via Web of Science (Royle 2003).
We have provided preliminary search strategies with the expected
time spans of the searches in Appendix 1. We will include reports
of trials in languages other than English, providing we can obtain
a reliable translation.
Searching other resources
We will identify other relevant studies by searching reference lists
of identified trials and conference proceedings.
We will also search on-line trial registries, such as Clinical-
Trial.gov (clinicaltrials.gov/), EuropeanMedicines Agency (EMA;
www.ema.europa.eu/ema/), WHO International Clinical Trial
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Registry Platform (www.who.int/ictrp), the Food and Drug Ad-
ministration (FDA; www.fda.gov), and pharmaceutical company
sources, for ongoing or unpublished trials.
Data collection and analysis
Wewill perform the review following Cochrane recommendations
(Higgins 2011), and the Cochrane Hepato-Biliary GroupModule
(Gluud 2017). We will use Review Manager 5 for the analyses
(RevMan 5 2014).
Selection of studies
Two review authors will independently review the titles and ab-
stracts of studies identified by the electronic searches and agree
on potential publications. We will retrieve the full text of all ap-
parently relevant studies. Two review authors will independently
assess the full text of potential studies for inclusion in the review
according to the pre-specified criteria. We will resolve differences
in opinion by discussion. In the event that we cannot resolve dif-
ferences, we will ask a third author to provide an opinion. We will
keep a record of all included and excluded studies that are selected
from the title review.
Data extraction and management
Wewill adapt the Cochrane Hepato-Biliary Group data collection
form and pilot this on one study (CHBG 2014). We will then use
the adapted form to record study characteristics from the included
studies on design, interventions, participants, and outcomes as
described in the Criteria for considering studies for this review
section above. Two review authors will independently extract the
data. We will resolve differences in extracted results by discussion,
and in the event of no agreement, we will ask a third author to
provide an opinion.
Assessment of risk of bias in included studies
Two review authorswill independently assess the risk of bias in each
of the included studies. We will use Cochrane criteria for judging
risk of bias in randomised studies (Higgins 2011). The Cochrane
’risk of bias’ tool criteria assess strictly ’random’ components as ’low
risk’ and ’non-random’ components as ’high risk’ of bias. We will
use the following definitions in our assessment (Kjaergard 2001;
Lundh 2012; Moher 1998; Savovic 2012; Savovic 2012a; Schulz
1995; Wood 2008).
Allocation sequence generation
• Low risk of bias: sequence generation was achieved using
computer random number generation or a random number
table. Drawing lots, tossing a coin, shuffling cards, and throwing
dice are adequate if performed by an independent person not
otherwise involved in the trial.
• Unclear risk of bias: the method of sequence generation was
not specified.
• High risk of bias: the sequence generation method was not
random. Such studies will be included only for assessments of
harms.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. Allocation
was controlled by a central and independent randomisation unit.
The allocation sequence was unknown to the investigators (for
example, if the allocation sequence was hidden in sequentially
numbered, opaque, and sealed envelopes).
• Unclear risk of bias: the method used to conceal the
allocation was not described, so that intervention allocations
may have been foreseen in advance of, or during, enrolment.
• High risk of bias: the allocation sequence was likely to be
known to the investigators who assigned the participants. Such
studies will be included only for assessments of harms.
Blinding of participants and personnel
• Low risk of bias: any of the following: no blinding or
incomplete blinding, but the review authors judge that the
outcome is not likely to be influenced by lack of blinding; or
blinding of participants and key study personnel ensured, and it
is unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ‘low risk’ or ‘high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding or
incomplete blinding, and the outcome is likely to be influenced
by lack of blinding; or blinding of key study participants and
personnel attempted, but likely that the blinding could have
been broken, and the outcome is likely to be influenced by lack
of blinding.
Blinded outcome assessment
• Low risk of bias: any of the following: no blinding of
outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of
blinding; or blinding of outcome assessment ensured, and
unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ‘low risk’ or ‘high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding of
outcome assessment, and the outcome measurement is likely to
be influenced by lack of blinding; or blinding of outcome
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assessment, but likely that the blinding could have been broken,
and the outcome measurement is likely to be influenced by lack
of blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. Sufficient
methods, such as multiple imputation, have been employed to
handle missing data.
• Unclear risk of bias: there was insufficient information to
assess whether missing data, in combination with the method
used to handle missing data, were likely to induce bias on the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported clinically relevant
outcomes (all-cause mortality and gallstone morbidity,
dissolution or reduction in size of gallstones, and serious adverse
events). If we have access to the original trial protocol, the
outcomes selected would be those called for in that protocol. We
will use information from trial registries such as
www.clinicaltrials.gov only if the investigators registered the trial
before inclusion of the first participant.
• Unclear risk of bias: it is unclear whether all clinically
relevant and reasonably expected outcomes were reported.
• High risk of bias: one or more clinically relevant and
reasonably expected outcomes were not reported.
For-profit bias
• Low risk of bias: the trial appears to be free of industry
sponsorship or other kind of for-profit support that may
manipulate the trial design, conduct, or results of the trial.
• Unclear risk of bias: the trial may or may not be free of for-
profit bias, as no information on clinical trial support or
sponsorship is provided.
• High risk of bias: the trial is sponsored by the industry, or
has received other kinds of for-profit support.
Other risk of bias
The following will be considered: baseline imbalance; deviation
from study protocol; pre-randomisation administration of the in-
tervention or inappropriate administration; sparse data bias, aca-
demic bias, early stopping for perceived benefit without an a priori
plan (Greenland 2016).
• Low risk of bias: the trial appears to be free of other sources
of bias.
• Uncertain risk of bias: there is insufficient information to
assess whether other sources of bias are present.
• High risk of bias: it is likely that potential sources of bias
related to the specific trial design used, or other bias risks, are
present.
We will consider trials to be at low risk of bias if assessed at ’low
risk of bias’ in all the above domains; in all other cases, we will
consider the trials at high risk of bias.
Measures of treatment effect
We will analyse outcomes measured as continuous data (such as
patient reported data using a visual analogue scale) using means
andmean differences with their corresponding standard deviations
and standard errors, and reported with 95% and Trial Sequen-
tial Analysis-adjusted confidence intervals (CIs). We will analyse
dichotomous data using odds ratios or risk ratios, and reported
with 95% and Trial Sequential Analysis-adjusted CIs. If trials have
multiple intervention groups, we will try to combine categories to
forms two groups (Higgins 2011).
Unit of analysis issues
The trial participants in a randomised clinical trial.
Dealing with missing data
We will try to find data on all participants who were randomised,
so that we can undertake intention-to-treat analyses, whichwill in-
clude all participants, regardless of adherence or complete follow-
up. In cases where outcome data for excluded participants have
not been published, we will contact the authors of the trial and
request their original data. We will gather information on non-
completing participants, including the time and reason for drop-
out, as described by the trial authors, and record this on the in-
formation extraction form. In addition, we will perform ’worst-
best case scenario’ and ’best-worst case scenario’ analyses for par-
ticipants lost to follow-up (Gluud 2017).
Assessment of heterogeneity
We will assess the presence of statistical heterogeneity using the
Chi² test. Where the P value is less than 0.1, we will assume there
is significant heterogeneity, and quantify heterogeneity using the
I² statistic (DerSimonian 1986; Higgins 2002). If intervention
studies are combined, errors may arise during the assessment of
heterogeneity due to differences in units of analysis. To address
this, we will use a fixed-effect analysis of comparisons within a trial
and then a random-effect analysis between trials.
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Assessment of reporting biases
We will develop a funnel plot using Review Manager 5 to eval-
uate bias by demonstrating the treatment effect against trial size
(RevMan 5 2014).
Data synthesis
Meta-analysis
We intend to undertake meta-analysis and present the findings ac-
cording to Cochrane recommendations (Higgins 2011). We will
combine data from trials with similar populations, interventions,
comparisons, and outcomes. If different scales are used tomeasure
the same outcome, we will present the standardised mean differ-
ence. We will calculate P values for all comparisons where this is
possible. We will undertake intention-to-treat analyses wherever
possible, so that all randomised patients are included. Where this
is not possible, we will carry out an analysis of available participant
cases.
If we include a small number of trials, or if the number of partici-
pants is small, we will use the Mantel-Haenszel method for pool-
ing dichotomous data, as this assumes a fixed-effect meta-analysis,
and is considered an appropriate method (Mantel 1959; Higgins
2011). For continuous data, we will use standardised or mean dif-
ferences to pool results. If there is no heterogeneity between study
findings, we will synthesise and analyse data using a fixed-effect
model meta-analysis (Demets 1987). If this is not possible, we will
use the random-effects model (DerSimonian 1986).
Trial Sequential Analysis
Where possible, we will examine apparently significant beneficial
and harmful intervention effects and neutral effects with Trial Se-
quential Analysis (Thorlund 2011;TSA2016), in order to evaluate
if these apparent effects could be caused by random error or ‘play
of chance’ (Brok 2008; Wetterslev 2008; Brok 2009; Thorlund
2009; Wetterslev 2009; Thorlund 2010).
We will perform Trial Sequential Analysis (TSA) on the data, pri-
marily from the trials with a low risk of bias (Brok 2008;Wetterslev
2008). However, if we do not identify any trials with low risk of
bias, we will discuss which trials to include. We will analyse the
outcomes using TSA, regardless of the statistical significance of
the results. The pooled estimate of the control event proportions
of the trials with low risk of bias will be used as the control event
proportion in the TSA. We will use the pooled estimate of the
intervention effect using the trials with low risk of bias, and also
perform a sensitivity analysis, using an intervention effect of a
20% risk ratio reduction. The unit of the intervention effect for
all dichotomous data will be risk ratio reduction.
For each TSA performed, we will calculate a diversity-adjusted re-
quired information size, based on the intervention effect suggested
by trials with a low risk of bias and an intervention effect of 20%
risk ratio reduction, a type I error risk of 2.0% and a type II error
risk of 10% (Wetterslev 2009). The diversity adjustment will be
performed using the observed diversity adjustment factor 1/(1 -
D²), the heterogeneity estimated by D² among all trials, and with
an assumed final diversity of 50% (Wetterslev 2009).
Subgroup analysis and investigation of heterogeneity
If there is apparent significant clinical heterogeneity, we will per-
form subgroup analyses. These will include trials at low risk of bias
compared to trials at high risk of bias, trials that included adults
compared to children (0 to 18 years); male compared to female;
gallstone type; acute versus chronic disease; body weight; body
mass index category, presence of diabetes compared to normogly-
caemia (Stinton 2010; Stokes 2014a; Aune 2016). If there is ap-
parent significant clinical heterogeneity between the trials, we will
specifically examine the degree of heterogeneity we observe in the
results with the I² statistic , using the guideline that an I² statistic
value of 50% or more indicates a substantial level of heterogeneity
(Higgins 2002; Higgins 2003).
Sensitivity analysis
If we identify a sufficient number of randomised trials, we will
perform sensitivity analyses to examine the impact of the following
factors on effect size:
• size of trials (e.g. large trials).
• trials identified using the following filters: diagnostic
criteria; language of publication; source of funding (industry
compared to other).
• duration of intervention (e.g. impact of short compared to
long interventions).
’Summary of findings’ tables
We will use the GRADE approach to evaluate the quality of the
evidence for outcomes reported in the review by considering the
within-study risk of bias (methodological quality), indirectness
of evidence (population, intervention, control, outcomes), unex-
plained heterogeneity or inconsistency of results (including prob-
lems with subgroup analyses); imprecision of effect estimate (wide
conference intervals as evaluated with our Trial Sequential Anal-
yses; Jakobsen 2014), and risk of publication bias (GRADEpro
GDT; Meader 2014). We will define the evidence as ’high’, ’mod-
erate’, ’low’, or ’very low’ certainty. These levels are defined as fol-
lows.
• High certainty: this research provides a very good
indication of the likely effect; the likelihood that the effect will
be substantially different is low.
• Moderate certainty: this research provides a good indication
of the likely effect; the likelihood that the effect will be
substantially different is moderate.
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• Low certainty: this research provides some indication of the
likely effect; however, the likelihood that it will be substantially
different is high.
• Very low certainty: this research does not provide a reliable
indication of the likely effect; the likelihood that the effect will
be substantially different is very high.
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A P P E N D I C E S
Appendix 1. Search strategy
Database Time span Search strategy
TheCochraneHepato-BiliaryGroupCon-
trolled Trials Register
Date of search (diet* AND fat* AND (restrict* OR modif*)) AND
(cholelithiasis OR gallstone* OR ’gall stone*’ OR gall-
stone*)
Cochrane Central Register of Controlled
Trials (CENTRAL) in the Cochrane Li-
brary
Latest issue #1 MeSH descriptor Nutrition Therapy explode all trees
#2 MeSH descriptor Dietary Fats explode all trees
#3 MeSH descriptor Diet, Fat-Restricted explode all trees
#4 diet* AND fat* AND (restrict* OR modif*)
#5 (#1 OR #2 OR #3 OR #4)
#6 MeSH descriptor Cholelithiasis explode all trees
#7 cholelithiasis OR gallstone* OR gall stone* OR gall-
stone*
#8 (#6 OR #7)
#9 (#5 AND #8)
MEDLINE Ovid 1946 to the date of search 1. exp Nutrition Therapy/
2. exp Dietary Fats/
3. exp Diet, Fat-Restricted/
4. (diet* and fat* and (restrict* or modif*)).mp. [mp=ti-
tle, abstract, original title, name of substance word, subject
heading word, protocol supplementary concept, rare dis-
ease supplementary concept, unique identifier]
5. 1 or 2 or 3 or 4
6. exp Cholelithiasis/
7. (cholelithiasis or gallstone* or gall stone* or gall-stone*)
.mp. [mp=title, abstract, original title, name of substance
word, subject heading word, protocol supplementary con-
cept, rare disease supplementary concept, unique identi-
fier]
8. 6 or 7
9. 5 and 8
10. (random* or blind* or placebo* or meta-analys*).mp.
[mp=title, abstract, original title, name of substance word,
subject heading word, protocol supplementary concept,
rare disease supplementary concept, unique identifier]
11. 9 and 10
Embase Ovid 1974 to the date of search 1. exp diet therapy/
2. exp fat intake/
3. (diet* and fat* and (restrict* or modif*)).mp. [mp=title,
abstract, subject headings, heading word, drug trade name,
original title, device manufacturer, drug manufacturer, de-
vice trade name, keyword]
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(Continued)
4. 1 or 2 or 3
5. exp cholelithiasis/
6. (cholelithiasis or gallstone* or gall stone* or gall-stone*)
.mp. [mp=title, abstract, subject headings, heading word,
drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword]
7. 5 or 6
8. 4 and 7
9. (random* or blind* or placebo* or meta-analys*).mp.
[mp=title, abstract, subject headings, heading word, drug
trade name, original title, device manufacturer, drug man-
ufacturer, device trade name, keyword]
10. 8 and 9
Science Citation Index Expanded (Web of
Science)
1900 to the date of search # 5 #4 AND #3
# 4 TS=(random* or blind* or placebo* or meta-analys*)
# 3 #2 AND #1
# 2 TS=(cholelithiasis or gallstone* or gall stone* or gall-
stone*)
# 1 TS=(diet* and fat* and (restrict* or modif*))
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